Tetanus Adjunct Treatment — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for tetanus adjunct treatment. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2044. Daily refresh.

1
Approved drugs
1
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Tetanus Adjunct Treatment

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Hikma 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating tetanus adjunct treatment. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Robaxin
METHOCARBAMOL
 Hikma 1 75 — 2044-10-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12390439 Robaxin method of use 75 2044-10-09

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12390439 Robaxin method of use 75 2044-10-09

Related